Of Four Aβ Antibodies, Only Aducanumab Stems Tide of Toxic Oligomers
Published 6 October 2020 Aducanumab was compared, in a blinded study, to three clinical-stage antibodies using chemical kinetics. The publication describes the use of chemical kinetic analysis to assess the mechanisms of action of four clinical stage anti-Aβ antibodies: aducanumab (Biogen), gantenerumab (Roche), bapineuzumab (Elan) and solanezumab (Eli Lilly). The results provide unique insights i
https://www.multipark.lu.se/article/four-ab-antibodies-only-aducanumab-stems-tide-toxic-oligomers - 2025-07-07